Locoregional Recurrence and Survival Outcomes in Breast Cancer Treated With Modern Neoadjuvant Chemotherapy: A Contemporary Population-based Analysis

医学 乳腺癌 肿瘤科 内科学 紫杉烷 蒽环类 乳房切除术 放射治疗 化疗 保乳手术 三阴性乳腺癌 新辅助治疗 人口 癌症 环境卫生
作者
Sonja Murchison,Alan Nichol,Caroline Speers,Lovedeep Gondara,Nathalie LeVasseur,Caroline Lohrisch,Isabelle Vallières,Pauline T. Truong
出处
期刊:Clinical Breast Cancer [Elsevier BV]
卷期号:22 (7): e773-e787
标识
DOI:10.1016/j.clbc.2022.07.003
摘要

Data guiding radiotherapy (RT) decisions after neoadjuvant chemotherapy (NAC) is largely retrospective, based on older treatment approaches without molecular subtype information. This study evaluated outcomes in breast cancer patients treated with modern NAC by molecular subtype and locoregional treatment.There were 949 patients diagnosed between 2005 and 2016 treated with NAC followed by surgery ± locoregional radiotherapy (LRRT). Outcomes were 7-year locoregional relapse-free survival (LRRFS), breast cancer-specific survival (BCSS), and overall survival (OS).Median follow-up was 6.5 years, 92% had cT2-4 and 72% cN1-3 disease. Subtypes were: 21% Luminal A, 18% Luminal B, 35% Her2+, and 21% triple-negative breast cancer (TNBC). Combined taxane and anthracycline-based NAC was used in 91.7% of cases. All patients with Her2+ disease received anti-Her2 therapy. After NAC, the majority (84.9%) underwent mastectomy, and received LRRT (86.1%). Only 11% had mastectomy without RT. Pathologic complete response (pCR) rates were 2.5% for Luminal A, 14.4% Luminal B, 27% TNBC, and 35.1% Her2+. Overall, adjuvant LRRT was associated with improved outcomes but was most significant for improved LRRFS in TNBC (92.5% vs. 68.5%, P < .001; Her2+ 95.4% vs. 93.6%, P = .81; Luminal A 97.4% vs. 100%, P = .49; Luminal B 89.7% vs. 100%, P = .17). On multivariable analysis, factors associated with reduced LRRFS were grade 3 histology (HR 4.96, P = .009) and no pCR (HR 7.0, P = .0008). Predictors of lower BCSS and OS were age >50, grade 3, cT3-4, lack of pCR, LRRT omission, and TNBC and Her2+ subtypes.In this analysis of patients treated with modern NAC, pCR rates varied by molecular subtype. Patients who did not receive LRRT, particularly those with TNBC, had lower survival compared to those treated with LRRT. These findings support the need for prospective studies to evaluate the safety of de-escalating RT after NAC.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
杉杉完成签到 ,获得积分10
刚刚
budingman发布了新的文献求助20
1秒前
budingman发布了新的文献求助20
1秒前
budingman发布了新的文献求助20
1秒前
budingman发布了新的文献求助20
1秒前
2秒前
budingman发布了新的文献求助20
3秒前
一颗橙子发布了新的文献求助10
5秒前
Akim应助陈泽采纳,获得10
5秒前
5秒前
大模型应助栀璃鸳挽采纳,获得10
6秒前
欢喜海发布了新的文献求助10
7秒前
黄新宇完成签到,获得积分10
8秒前
鲁鱼完成签到,获得积分10
12秒前
12秒前
费老五完成签到 ,获得积分10
15秒前
鲁鱼发布了新的文献求助10
17秒前
英姑应助巴黎的防采纳,获得10
17秒前
欢喜海完成签到,获得积分10
18秒前
zakai完成签到 ,获得积分10
18秒前
烟花应助45度人采纳,获得20
20秒前
彭于晏应助budingman采纳,获得20
20秒前
22秒前
yuchangkun发布了新的文献求助10
24秒前
Corundum发布了新的文献求助10
26秒前
顾矜应助淡定海亦采纳,获得10
28秒前
29秒前
小刘完成签到,获得积分10
30秒前
Shirley完成签到 ,获得积分10
31秒前
善学以致用应助yuchangkun采纳,获得10
32秒前
欻欻完成签到,获得积分10
32秒前
33秒前
33秒前
斯文败类应助刺槐采纳,获得10
35秒前
香蕉觅云应助姜宇航采纳,获得10
36秒前
36秒前
37秒前
野猪大王完成签到 ,获得积分10
38秒前
wanci应助与落采纳,获得10
38秒前
高分求助中
Ophthalmic Equipment Market by Devices(surgical: vitreorentinal,IOLs,OVDs,contact lens,RGP lens,backflush,diagnostic&monitoring:OCT,actorefractor,keratometer,tonometer,ophthalmoscpe,OVD), End User,Buying Criteria-Global Forecast to2029 2000
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 588
不知道标题是什么 500
A Preliminary Study on Correlation Between Independent Components of Facial Thermal Images and Subjective Assessment of Chronic Stress 500
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3962497
求助须知:如何正确求助?哪些是违规求助? 3508510
关于积分的说明 11141528
捐赠科研通 3241254
什么是DOI,文献DOI怎么找? 1791452
邀请新用户注册赠送积分活动 872876
科研通“疑难数据库(出版商)”最低求助积分说明 803455